PDCD1 and hepatocellular carcinoma: It is noteworthy that the immunotherapy combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA-4-targeted antibody Yervoy (ipilimumab) is the first dual-immune-checkpoint-inhibitor regimen approved for the treatment of advanced HCC patients [12].